Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Forecast, Price & News $26.88 -1.00 (-3.59%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$26.57▼$28.1250-Day Range$26.88▼$36.6152-Week Range$26.57▼$52.40Volume1.39 million shsAverage Volume956,407 shsMarket Capitalization$2.58 billionP/E RatioN/ADividend YieldN/APrice Target$58.21 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Cytokinetics MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside116.6% Upside$58.21 Price TargetShort InterestBearish13.69% of Float Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment0.26Based on 3 Articles This WeekInsider TradingSelling Shares$2.55 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.10) to ($3.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector416th out of 966 stocksPharmaceutical Preparations Industry179th out of 442 stocks 4.5 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $58.21, Cytokinetics has a forecasted upside of 116.6% from its current price of $26.88.Amount of Analyst CoverageCytokinetics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.69% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cytokinetics has recently increased by 8.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 73.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.64. Previous Next 1.8 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cytokinetics this week, compared to 3 articles on an average week.Search Interest11 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,551,200.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.10) to ($3.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Cytokinetics (NASDAQ:CYTK) StockCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesOctober 3, 2023 | markets.businessinsider.comRising Prescription Rates and Market Shifts: A Positive Outlook for CytokineticsOctober 2, 2023 | finance.yahoo.comCytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific MeetingOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 23, 2023 | finance.yahoo.comCytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia GravisSeptember 18, 2023 | seekingalpha.comCytokinetics: Clinical Efficacy Isn't Enough For SuccessSeptember 15, 2023 | finance.yahoo.comEVP Research & Development Fady Malik Sells 2,500 Shares of Cytokinetics IncSeptember 14, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Alnylam Pharma (ALNY)September 14, 2023 | finance.yahoo.comInsider Sell: Cytokinetics Inc's President & CEO Robert Blum Sells 12,500 SharesOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 6, 2023 | finance.yahoo.comCytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic CardiomyopathyAugust 15, 2023 | msn.comSVB Leerink Initiates Coverage of Cytokinetics (CYTK) with Outperform RecommendationAugust 7, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)August 5, 2023 | msn.comMorgan Stanley Reiterates Cytokinetics (CYTK) Overweight RecommendationAugust 4, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Hold Rating for Cytokinetics (CYTK)August 3, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Cytokinetics (CYTK)August 3, 2023 | finance.yahoo.comCytokinetics Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | finanznachrichten.deCytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)July 28, 2023 | markets.businessinsider.comCytokinetics (CYTK) Receives a Buy from Mizuho SecuritiesJuly 28, 2023 | finance.yahoo.comCytokinetics to Announce Second Quarter Results on August 3, 2023July 27, 2023 | finance.yahoo.comCytokinetics' (NASDAQ:CYTK) investors will be pleased with their enviable 361% return over the last five yearsJuly 27, 2023 | thestreet.comWhy Cytokinetics (CYTK) Stock Is Plummeting Today (Update)July 10, 2023 | seekingalpha.comAficamten Sets Cytokinetics Apart In CardiomyopathyJune 28, 2023 | bizjournals.comAfter 25 years, Peninsula company believes it has right recipe to bring 1st drug to marketJune 26, 2023 | markets.businessinsider.comPiper Sandler Remains a Buy on Cytokinetics (CYTK)June 22, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Verve Therapeutics (VERV) and Cytokinetics (CYTK)June 21, 2023 | thestreet.comCytokinetics (CYTK) Stock Rises Today After Roth Capital Increases Price TargetJune 20, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Cytokinetics (CYTK)See More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees409Year Founded1997Price Target and Rating Average Stock Price Forecast$58.21 High Stock Price Forecast$80.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+116.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-388,950,000.00 Net Margins-5,419.17% Pretax Margin-5,422.19% Return on EquityN/A Return on Assets-55.00% Debt Debt-to-Equity RatioN/A Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$94.59 million Price / Sales27.28 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-23.58Miscellaneous Outstanding Shares96,000,000Free Float92,350,000Market Cap$2.58 billion OptionableOptionable Beta0.80 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 59)CEO, Pres & Director Comp: $1.14MMr. Ching W. Jaw (Age 60)Sr. VP & CFO Comp: $698.49kMr. Robert C. Wong (Age 55)VP & Chief Accounting Officer Comp: $463.75kDr. Fady Ibraham Malik FACC (Age 59)M.D., Ph.D., Exec. VP of R&D Comp: $776.99kMr. Andrew M. Callos (Age 67)Exec. VP & Chief Commercial Officer Comp: $745.4kDr. James A. Spudich Ph.D. (Age 81)Co-Founder & Member of Scientific Advisory Board Mr. Jeff LotzVP of Sales & OperationsMr. Steven M. Cook (Age 64)Sr. VP of Supply Chain Operations & Technical Operations Ms. Diane WeiserSr. VP of Corp. Communications & Investor RelationsMs. Kari K. Loeser J.D.VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLMirati TherapeuticsNASDAQ:MRTXProthenaNASDAQ:PRTAUltragenyx PharmaceuticalNASDAQ:RAREAkero TherapeuticsNASDAQ:AKROView All CompetitorsInsiders & InstitutionsBarclays PLCSold 195,926 shares on 9/21/2023Ownership: 0.151%Fady Ibraham MalikSold 2,500 sharesTotal: $87,150.00 ($34.86/share)Robert I BlumSold 12,500 sharesTotal: $436,250.00 ($34.90/share)Farther Finance Advisors LLCSold 476 shares on 9/12/2023Ownership: 0.001%Robert I BlumSold 12,500 sharesTotal: $424,875.00 ($33.99/share)View All Insider TransactionsView All Institutional Transactions CYTK Stock - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price forecast for 2023? 14 brokerages have issued twelve-month target prices for Cytokinetics' shares. Their CYTK share price forecasts range from $42.00 to $80.00. On average, they anticipate the company's stock price to reach $58.21 in the next year. This suggests a possible upside of 116.6% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2023? Cytokinetics' stock was trading at $45.82 on January 1st, 2023. Since then, CYTK stock has decreased by 41.3% and is now trading at $26.88. View the best growth stocks for 2023 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 12,550,000 shares, an increase of 8.1% from the August 31st total of 11,610,000 shares. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 15.7 days. Currently, 13.7% of the company's stock are short sold. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.11. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $5.67 million. Cytokinetics's revenue was down 99.0% on a year-over-year basis. During the same period last year, the company posted ($0.23) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED). What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). What is Cytokinetics' stock symbol? Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK." How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytokinetics' stock price today? One share of CYTK stock can currently be purchased for approximately $26.88. How much money does Cytokinetics make? Cytokinetics (NASDAQ:CYTK) has a market capitalization of $2.58 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. How many employees does Cytokinetics have? The company employs 409 workers across the globe. How can I contact Cytokinetics? Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010. This page (NASDAQ:CYTK) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.